TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Pérez, Cristina ^a   Martínez Calle, Nicolas ^a   Martín Subero, José Ignacio ^b   Segura, Victor ^c   Delabesse, Eric ^d   Fernandez Mercado, Marta ^e   Garate, Leire ^a   Alvarez, Sara ^f   Rifon, José ^g   Varea, Sara ^g   Boultwood, Jacqueline ^e   Wainscoat, James S ^e   Cigudosa, Juan Cruz ^f   Calasanz, María José ^a   Cross, Nicholas C P ^h,i   Prósper, Felipe ^a,g   Agirre, Xabier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d CHU PURPAN   (France)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f Centro Nacional de Investigaciones Oncológicas   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; STRESS ACTIVATED PROTEIN KINASE; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; EZH2 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; ONCOPROTEIN; TET2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EZH2 GENE; GENE CLUSTER; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; JAK2 GENE; KARYOTYPE; MUTATIONAL ANALYSIS; ONCOGENE; TET2 GENE; WILD TYPE; BIOLOGY; DNA MICROARRAY; GENETICS; MUTATION;

5-METHYLCYTOSINE; COMPUTATIONAL BIOLOGY; CYTOSINE; DNA METHYLATION; DNA-BINDING PROTEINS; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 84856657348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031605     Document Type: Article

References (50)

1. Elliott MA, (2006) Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Pract Res Clin Haematol 19: 571-593.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
3. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, et al. (2010) Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28: 3858-3865.
4. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, et al. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106: 3377-3379.
5. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726.
6. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, et al. (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116: 3923-3932.
7. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, et al. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145: 788-800.
8. Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, et al. (2006) Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 126: 530-533.
9. Li Z, Cai X, Cai C, Wang J, Zhang W, et al. (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011 Jul 29 [Epub ahead of print].
10. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, et al. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11-24.
11. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, et al. (2011) TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. Cancer Cell 20: 25-38.
12. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, et al. (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114: 3285-3291.
13. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, et al. (2010) Role of Tet proteins in 5 mC to 5 hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466: 1129-1133.
14. Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, et al. (2010) TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 20: 1390-1393.
15. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, et al. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839-843.
16. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, et al. (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109: 52-57.
17. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP, (2008) Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111: 2382-2384.
18. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835-3849.
19. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168.
20. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, et al. (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95: 1668-1674.
21. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
22. Bibikova M, Le J, Barnes B, Saedinia-Melnick S, Zhou L, et al. (2009) Genome wide DNA methylation profiling using the Infinium assay. Epigenomics 1: 177-200.
23. Sturn A, Quackenbush J, Trajanoski Z, (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18: 207-208.
24. Gentleman RC, Huber W, Irizarry R, Dudoit S, (2005) Bioinformatics and Computational Biology Solutions Using R and Bioconductor. In: Heathcare S, editors. Statistics for Biology and Health UK.
25. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
26. Cheadle C, Vawter MP, Freed WJ, Becker KG, (2003) Analysis of microarray data using Z score transformation. J Mol Diagn 5: 73-81.
27. Draghici S, Khatri P, Eklund AC, Szallasi Z, (2006) Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 22: 101-109.
28. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
29. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466.
30. Vilas-Zornoza A, Agirre X, Martin-Palanco V, Martin-Subero JI, San Jose-Eneriz E, et al. (2011) Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS One 6: e17012.
31. Xiao W, Ando T, Wang HY, Kawakami Y, Kawakami T, (2010) Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. Blood 116: 6003-6013.
32. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, et al. (2009) Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 16: 161-171.
33. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
34. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, et al. (2009) New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113: 2488-2497.
35. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, et al. (2011) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. Blood 2011 Aug 9 [Epub ahead of print].
36. Such E, Cervera J, Costa D, Sole F, Vallespi T, et al. (2010) Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 96: 375-383.
37. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, et al. (2011) Activity of azacitidine in chronic myelomonocytic leukemia. Cancer.
38. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, et al. (2010) Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116: 3163-3170.
39. Voso MT, Santini V, Finelli C, Musto P, Pogliani E, et al. (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15: 5002-5007.
40. Stephenson J, Akdag R, Ozbek N, Mufti GJ, (1993) Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia. Leuk Res 17: 291-293.
41. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, et al. (2003) Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 17: 910-918.
42. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315-1325.
43. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, et al. (2010) DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115: 1214-1225.
44. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984.
45. Shannon K, Van Etten RA, (2005) JAKing up hematopoietic proliferation. Cancer Cell 7: 291-293.
46. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, et al. (2010) Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70: 1042-1052.
47. Yang SH, Wu ZZ, Chien CM, Lo YH, Wu MJ, et al. (2008) JNK and ERK mitogen-activated protein kinases mediate THDA-induced apoptosis in K562 cells. Cell Biol Toxicol 24: 291-302.
48. Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, et al. (2008) c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia 22: 1899-1908.
49. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, et al. (2011) Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 25: 877-879.
50. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.